Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
Matthew During, Darien, CT (US); and Brett Abrahams, New York, NY (US)
Assigned to OVID THERAPEUTICS INC., New York, NY (US)
Filed by Ovid Therapeutics Inc., New York, NY (US)
Filed on Apr. 19, 2023, as Appl. No. 18/302,997.
Application 18/302,997 is a continuation of application No. 17/072,511, filed on Oct. 16, 2020, granted, now 11,660,277.
Application 17/072,511 is a continuation of application No. 16/434,300, filed on Jun. 7, 2019, granted, now 10,813,899, issued on Oct. 27, 2020.
Claims priority of provisional application 62/681,913, filed on Jun. 7, 2018.
Prior Publication US 2023/0255914 A1, Aug. 17, 2023
1. A method of treating fragile X-associated tremor/ataxia syndrome comprising administering (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject having fragile X-associated tremor/ataxia syndrome in an amount of from about 0.001 mg to about 750 mg.